Xbrane Biopharma Ab · OMXSTO:XBRANE
Xbrane Biopharma Ab — Investor Presentation (April 2025)
21 slides from Xbrane Biopharma Ab's investor presentation, April 2025
Slide 1: Company Presentation
STO: XBRANE April 2025 Company Presentation 1
Slide 2: Important information
Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in
Slide 3: Agenda
Agenda Overview Ximluci® / Lucamzi Xdivane Financial outlook 3
Slide 4: Xbrane – Investment highlights
Xbrane – Investment highlights Xbrane is a derisked opportunity in the biosimilar space Portfolio & Company highlights → Xbrane is a late-stage biosimilar developer set to capitalize on Listing Market Cap one commercial and one Phase 3 asset Headquarters NASDAQ SEK 304m → Ximluci® (Lucentis biosimil
Slide 5: Transformative sale for Xbrane of XB003 to Alvotech
Transformative sale for Xbrane of XB003 to Alvotech On 20 March 2025, Xbrane announced that it had entered into an agreement to sell XB003 and parts of its organization to Alvotech for a total consideration of SEK 275 million, marking a transformational transaction for the Company → Sale of XB003 re
Slide 6: Derisked biosimilar portfolio set to generate profitability
Derisked biosimilar portfolio set to generate profitability Biosimilar candidate Ximluci® (ex-US) Lucamzi (US) Xdivane Reference product Therapeutic area Ophthalmology Oncology Dec 2028 (US) Patent expiry 2022 (EU) 2020 (US) June 2030 (EU) Development phase Commercial (Europe, MENA) Registration Ent
Slide 7: Biosimilar market expected to grow to USD 74bn by 2030
Biosimilar market expected to grow to USD 74bn by 2030 Biologics with >USD 260bn in sales lose exclusivity by 2032 Biosimilar market to grow by 17% per year through to 2030 Estimated cumulative global annual peak sales, USD billion Global biosimilar sales, USD billion 74.0 61.5 54.5 51.6 35.4 32.9 1
Slide 8: Agenda
Agenda Overview Ximluci® / Lucamzi Xdivane Financial outlook 8
Slide 9: Ximluci® / Lucamzi – Market & landscape
Ximluci® / Lucamzi – Market & landscape Global anti-VEGF therapeutics market Landscape & Commentary 18 → Ximluci® is one of 3 Lucentis (ranibizumab) biosimilars currently available: 16 → Byooviz – Biogen 14 → Cimerli – Sandoz US / Ranvisio – Teva Europe 12 → In the US biosimilars have now claimed a
Slide 10: Ximluci® – Commercial status Europe & RoW
Ximluci® – Commercial status Europe & RoW Ximluci® launched by STADA in 22 countries Co-Development & Commercialization Partnership with STADA Partnership with STADA signed in 2018. STADA are granted the commercial rights to Ximluci® globally → Global generics and biosimilar specialist with includin
Slide 11: Ximluci® – Performance in launched markets & opportunity
Ximluci® – Performance in launched markets & opportunity Profit split to Xbrane and growth in vials sold by STADA Commentary 94.7 → Current inventory with value of SEK 180m to be converted into 88.6 cash during 2026-2028 as more product is delivered to STADA → Total profit sharing to Xbrane since la
Slide 12: Lucamzi – Status US
Lucamzi – Status US Xbrane & STADA partner with Valorum US Commercialization Partnership Xbrane and STADA license US commercial rights to Valorum Biologics. Valorum will be responsible for sales, → Biosimilar commercialization marketing and commercial efforts in the US after approval. STADA are resp
Slide 13: Lucamzi – US opportunity
Lucamzi – US opportunity US retinal anti VEGF: USD 10 billion market Commentary ~8 million units → Lucentis biosimilars covered under Medicare Part B with 20% 100% patient co-payment → Reimbursement based on ASP* + 6-8% of originator ASP 80% → Dynamic which favors new biosimilar entrants starting fr
Slide 14: Agenda
Agenda Overview Ximluci® / Lucamzi Xdivane Financial outlook 14
Slide 15: Xdivane – Market & landscape
Xdivane – Market & landscape Opdivo® expected to generate net-sales of $14b globally in 2028 Landscape & Commentary → Opdivo is an immuno-oncology drug (PD1 inhibitor) used in treatment of several cancers including melanoma and lung 15 cancer → The total global market for PD1/PDL1 inhibitors is esti
Slide 16: Xdivane – Global partnership with Intas
Xdivane – Global partnership with Intas Partnership with Intas Global License & Co-Development Agreement Exclusive agreement with Intas signed in 2024. Intas will finance and oversee clinical and regulatory development activities as well as global manufacturing and commercialization through its subs
Slide 17: Xdivane – Streamlined development agreed with EMA & FDA
Xdivane – Streamlined development agreed with EMA & FDA 2024 2025 2026 2027 2028 2029 2030 Commercialization Milestone payment to Milestone payment to Xbrane Xbrane LoE US LoE Europe Production of clinical material Pivotal clinical trial MAA / BLA → Successful scale-up to → Single pivotal trial with
Slide 18: Xdivane – Market dynamics & opportunity
Xdivane – Market dynamics & opportunity US biosimilar volume market share vs. reference product Commentary → Oncology biosimilars have been well received with average penetration of 75% at year 3 post launch in US → Sold via hospital channel in US under Medicare Part B reimbursement scheme with stro
Slide 19: Agenda
Agenda Overview Ximluci® / Lucamzi Xdivane Financial outlook 19
Slide 20: Strong growth in product & license related gross profit in 2024
Strong growth in product & license related gross profit in 2024 Historical Revenue Split and P&L Commentary → In 2024, product sales mostly related to profit sharing P&L Overview (SEK, million) 2021A 2022A 2023A 2024A → In 2023, 18% of product sales was related to profit sharing and License revenues
Slide 21: Xbrane’s cumulative financial profile, product by product
Xbrane’s cumulative financial profile, product by product Ximluci® + Lucamzi + Xdivane Gross Margin: 40-55% 55-65% +85% EBITDA Margin: 20-40% 40-50% +80% Assumptions: • Xbrane’s first • US FDA approval and • US FDA approval in commercial asset launch in US in 2026 December 2028 • 7.5% volume market
Xbrane Biopharma — Investor Presentation (April 2025) on 6ix